Pasqal, FormFactor and Keysight: Quantum’s Quieter Bets

Yesterday’s market opened like any other day – the S&P, Nasdaq and Dow all nudged lower – but the little‑world of quantum‑computing stocks behaved like strangers at a party. While the broader indexes drifted down about half a percent, FormFactor (FORM) was busy climbing 4.4%, and pure‑play names like IonQ (IONQ) and D‑Wave (QBTS) were quietly losing ground.

It might sound like a minor wobble, but the split is meaningful. For most of the sector’s short history, every quantum ticker moved in lock‑step, all priced on the same far‑off promise: a computer that can juggle qubits instead of bits, cracking problems that today’s silicon can’t. When that narrative shifts, the stocks begin to reveal their true business models.

Enter the three names that MarketBeat is now pointing out as “quieter” bets. Pasqal (PSQL) still looks a lot like a pure‑play – a low‑priced, lightly covered stock that the market treats more like an option on a future breakthrough than a profit‑generating company. Its share hovered just under $8, trading in a tight $7.80‑$8.17 range, and the chatter around it remains very much about hope rather than earnings.

FormFactor, on the other hand, is a different animal. It makes the probe cards and cryogenic test gear that let chip designers – quantum or otherwise – verify that their silicon actually works. In other words, FormFactor gets paid every time an experiment runs, regardless of whether the qubit architecture eventually wins the race. That upstream role kept it insulated from the day‑to‑day sentiment swing, letting it post a 4.4% gain even as the Nasdaq 100 fell.

Keysight Technologies (KEYS) occupies the third spot. At $330 a share, it sits comfortably in the middle of a broad instrumentation business that serves labs, defense projects and commercial developers alike. Quantum is just one line on its massive order book, not the whole story. Its modest 1% dip mirrored the overall market, reinforcing the idea that its fortunes are tied to a wider set of customers.

So what does this tell an investor? First, the pure‑play stocks – IonQ at $38.92 and D‑Wave at $17.45 – are still the headline makers. When they slip, it mainly signals that investors are pulling back on long‑duration, pre‑revenue bets. It doesn’t automatically mean that companies selling test equipment are seeing fewer orders; their revenue streams are simply less tied to the hype.

Second, the macro backdrop matters. Long‑duration equities, like pure‑play quantum firms, are especially sensitive to changes in interest rates and discount factors. A market that’s broadly softer will tend to hammer down those speculative names first.

Third, transparency could rewrite the story. Right now, suppliers like FormFactor and Keysight don’t break out quantum revenue as a separate line because it’s still a tiny slice of a much larger pie. If they start reporting it more clearly, investors might re‑price the risk and reward profile – either narrowing the gap with the pure plays or widening it further.

Finally, capital availability is a wild card. Pasqal’s low price reflects the market’s demand for concrete proof before committing cash. If the sentiment around pure plays stays chilly, financing could become more expensive, which in turn could hamper the very R&D that the pure plays rely on.

Bottom line: a single day of divergence isn’t a trend, but it does hint that the quantum theme is maturing. The conversation is moving from “Will the machine ever work?” to “Who gets paid while we’re figuring that out?” That shift—from narrative to revenue—will likely define the next chapter for all three stocks.